Producer
VINS Bioproducts
Major Indian antivenom maker; supplies Asian and African markets.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input VINS Bioproducts supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something VINS Bioproducts makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Antivenom (Anti-Snake Venom Serum)
Other Biologicals
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2024
The only effective treatment for a venomous snakebite is made by a process essentially unchanged for over a century — inside horses. To produce antivenom, makers like India's VINS Bioproducts inject small, escalating doses of snake venom (hand-milked from live snakes) into horses, let the animals' immune systems generate antibodies over months, then draw their blood and purify the plasma into antivenom serum. So the supply of a life-saving medicine for a condition that kills well over 100,000 people a year worldwide depends on herds of immunized horses and on the laborious milking of venomous snakes — 19th-century animal-immunization biology, not modern biotech. That makes antivenom hard to scale, hard to standardize, and chronically under-supplied: there's no quick way to ramp horse herds, and each batch's potency varies. It's one of the starkest examples in medicine of an essential antidote stuck on an artisanal, animal-dependent production method, leaving a global health need perpetually at the mercy of a slow, low-tech biological supply chain. [verify: horse-derived antivenom, VINS process, snakebite deaths >100k/yr established]
VINS Bioproducts Limited ↗Incident2024
Snakebite antivenom suffers a deadly mismatch between geography and biology, and India sits at its center. India has the world's highest snakebite death toll, and a few Indian makers (VINS, Bharat Serums, Premium Serums) supply much of the world's antivenom. But Indian polyvalent antivenom is raised against India's "Big Four" snakes (cobra, krait, Russell's viper, saw-scaled viper) — so it is often poorly effective or ineffective against the very different venoms of African and some Southeast Asian snakes. Yet because it is cheap and available, Indian-made antivenom has been widely exported to sub-Saharan Africa, where it can fail to neutralize local venoms, contributing to treatment failures and deaths. The crisis deepened when a maker of an effective Africa-specific antivenom halted production in the 2010s, leaving a gap filled by mismatched products. The World Health Organization classifies snakebite envenoming as a neglected tropical disease precisely because of this broken supply chain: the available, affordable antidote frequently doesn't match the snakes it's used against, an avoidable mismatch that costs lives across the developing world.
VINS Bioproducts / WHO ↗